Comparative Pharmacology
Head-to-head clinical analysis: BRETHINE versus ISOETHARINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRETHINE versus ISOETHARINE HYDROCHLORIDE.
BRETHINE vs ISOETHARINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; stimulates adenylate cyclase, increasing intracellular cAMP, leading to relaxation of bronchial smooth muscle and inhibition of mast cell mediator release.
ISOETHARINE HYDROCHLORIDE is a beta-2 adrenergic receptor agonist that stimulates adenylate cyclase, increasing cyclic AMP (cAMP) in bronchial smooth muscle, leading to bronchodilation. It also has beta-1 activity at higher doses, causing cardiac stimulation.
5 mg orally three times daily; may increase to 10 mg if needed; maximum 20 mg daily. Subcutaneous: 0.25 mg, may repeat once in 15-30 minutes (not to exceed 0.5 mg in 4 hours).
Inhalation via nebulizer: 0.5 mL (2.5 mg) of 0.5% solution diluted in 2-3 mL normal saline, administered over 10-20 minutes, every 4-6 hours as needed.
None Documented
None Documented
3-8 hours (terminal); shorter in children and smokers; prolonged in hepatic impairment
1.6 to 2.7 hours in adults; may be prolonged in patients with hepatic or renal impairment.
Renal: 50-60% as unchanged drug and metabolites; biliary/fecal: 20-30%
Primarily renal excretion of unchanged drug and metabolites; approximately 60-80% of a dose is excreted in urine within 24 hours, with the remainder excreted in feces via biliary elimination.
Category C
Category C
Beta-2 Adrenergic Agonist
Beta-2 Adrenergic Agonist